Abstract
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder representing the most common form of dementia and the most feared highly disabling age-related condition of our time. Hallmarks of AD include a dramatically increasing number of cases due to prospected demographics and the absence of a cure. AD is incurable as it escapes the formula “one disease, one mechanism, one drug”. AD has a multifaceted pathophysiology only in part uncovered. Even the proven chronological primacy of free radical-related damage in AD-related neurodegeneration has not yield successful oxidative stress – lowering trial designs. As a consequence, clinical trials of antioxidants in AD have brought largely negative conclusions. The aims of this review are to discuss 1. rationale for antioxidant trials, 2. reasons for failure of antioxidants in AD therapy, 3. potential preventive benefits of natural nutrition against AD onset and 4. the enormous relevance of detecting and treating AD risk factors as long as possible prior to AD manifestation.
Keywords: Clinical trial, antioxidant, oxidative stress, free radical, Alzheimer's disease, mild cognitive impairment.
Current Pharmaceutical Design
Title:Antioxidant Clinical Trials in Mild Cognitive Impairment and Alzheimer’s disease – Challenges and Perspectives
Volume: 20 Issue: 18
Author(s): Maria Cristina Polidori and Gereon Nelles
Affiliation:
Keywords: Clinical trial, antioxidant, oxidative stress, free radical, Alzheimer's disease, mild cognitive impairment.
Abstract: Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder representing the most common form of dementia and the most feared highly disabling age-related condition of our time. Hallmarks of AD include a dramatically increasing number of cases due to prospected demographics and the absence of a cure. AD is incurable as it escapes the formula “one disease, one mechanism, one drug”. AD has a multifaceted pathophysiology only in part uncovered. Even the proven chronological primacy of free radical-related damage in AD-related neurodegeneration has not yield successful oxidative stress – lowering trial designs. As a consequence, clinical trials of antioxidants in AD have brought largely negative conclusions. The aims of this review are to discuss 1. rationale for antioxidant trials, 2. reasons for failure of antioxidants in AD therapy, 3. potential preventive benefits of natural nutrition against AD onset and 4. the enormous relevance of detecting and treating AD risk factors as long as possible prior to AD manifestation.
Export Options
About this article
Cite this article as:
Polidori Cristina Maria and Nelles Gereon, Antioxidant Clinical Trials in Mild Cognitive Impairment and Alzheimer’s disease – Challenges and Perspectives, Current Pharmaceutical Design 2014; 20 (18) . https://dx.doi.org/10.2174/13816128113196660706
DOI https://dx.doi.org/10.2174/13816128113196660706 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nuclear Hormone Receptors and Female Reproduction
Current Molecular Medicine Antioxidant Properties of Nitric Oxide in Cellular Physiological and Pathophysiological Mechanisms. The Implications of Biological Balance between NO and Oxidative Stress
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Formulation and Evaluation of Extended Release Asymmetric Membrane Capsules of Atenolol
Current Drug Delivery Atherogenesis in White Coat Hypertension
Current Hypertension Reviews Preface
Current Pharmaceutical Design Editorial (Thematic Issue: Is The Female Heart Exposed To Cardiovascular Disease?)
Current Medicinal Chemistry Sex-Genetic Interaction in the Risk for Cerebrovascular Disease
Current Medicinal Chemistry Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design All for Statins and Statins for All; An Update
Current Pharmaceutical Design Apoptosis and Oxidative Stress-Related Diseases: The p66Shc Connection
Current Molecular Medicine Atheroma Burden and Morphology in Women
Current Pharmaceutical Design Metabolic Syndrome, Mild Cognitive Impairment and Dementia
Current Alzheimer Research Prevention of Ischemic Stroke: Surgery
Current Drug Targets Adipose Tissue as a Regulator of Energy Balance
Current Drug Targets Uncovering the Diversification of Tissue Engineering on the Emergent Areas of Stem Cells, Nanotechnology and Biomaterials
Current Stem Cell Research & Therapy Oxidative Stress Genes, Antioxidants and Coronary Artery Disease in Type 2 Diabetes Mellitus
Cardiovascular & Hematological Agents in Medicinal Chemistry Insulin Resistance-Induced Hypertension and a Role of Perivascular CGRPergic Nerves
Current Protein & Peptide Science Anti-diabetic Drug Metformin: Challenges and Perspectives for Cancer Therapy
Current Cancer Drug Targets Left Ventricular Hypertrophy Beyond Hemodynamics: Genetic, Metabolic and Hormonal Factors
Current Hypertension Reviews Bioenergetics and Mitochondrial Dysfunction in Aging: Recent Insights for a Therapeutical Approach
Current Pharmaceutical Design